Table 3.
Survival analysis of lenalidomide in DLBCL
| Secondary outcomes | No. of studies | No. of patients | I2 (%) | P value for heterogeneity | HR (95%CI) | P value for effects model |
|---|---|---|---|---|---|---|
| PFS | ||||||
| ALL | 5 | 1899 | 3.6 | 0.386 | 0.77 (0.66, 0.90) | 0.001 |
| Disease status | ||||||
| Untreated | 4 | 1790 | 10.1 | 0.343 | 0.79 (0.67, 0.94) | 0.006 |
| Regimen | ||||||
| R-CHOP based | 3 | 1549 | 0 | 0.550 | 0.75 (0.62, 0.90) | 0.002 |
| Median age | ||||||
| ≥ 65 | 5 | 1899 | 3.6 | 0.386 | 0.77 (0.66, 0.90) | 0.001 |
| Subtype | ||||||
| Non-GCB | 3 | 834 | 47.6 | 0.148 | 0.83(0.66, 1.05) | 0.125 |
| GCB | 3 | 350 | 0 | 0.484 | 0.70 (0.48, 1.03) | 0.070 |
| OS | ||||||
| ALL | 5 | 1601 | 0 | 0.592 | 0.99 (0.83, 1.20) | 0.950 |
| EFS | ||||||
| ALL | 3 | 847 | 0 | 0.818 | 0.99 (0.81, 1.21) | 0.927 |
Italic values indicate P < 0.05
EFS event-free survival, PFS progression-free survival, OS overall survival, 95%CI 95% confidence interval, HR hazard ratio, R-CHOP rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, GCB germinal center type